Any current/future new fundraising through debt or equity?

There is no specific mention of any current or planned fundraising through debt or equity in the transcript. The company has strengthened its financial position by reducing debt, which has lowered its interest burden and created headroom for future expansion and strategic investments. Capex plans for FY26 include approximately INR130 crores for the grain-based ethanol facility and investments in debottlenecking bio-based chemicals and biobutanol projects. The company is working on detailed engineering packages for expansion but has not provided firm capital expenditure figures or fundraising r

Any current/future capex/capital investment/strategic investment?

Godavari Biorefineries is investing in a grain/maize-based ethanol facility with a capacity of 200,000 liters per day, expected to be commissioned in Q4 FY26, with an estimated capex of INR 130 crores (net of GST). The company is undertaking debottlenecking initiatives to optimize bio-based specialty chemical production capacity, supporting growth in this segment. Engineering work is underway for a biobutanol project licensed from Catalyxx, which will expand their sustainable chemistry portfolio; detailed engineering design is in progress. Continuous maintenance capex is also planned ann

Future growth expectations in sales/revenue/volumes?

Godavari Biorefineries targets a 3x increase in EBITDA by FY29, driven by growth in ethanol and bio-based specialty chemicals. Ethanol segment growth supported by commissioning of 200-kiloliter/day grain/maize-based distillery in Q4 FY26, adding multi-feedstock capacity. Continued de-bottlenecking and capacity expansions planned for bio-based chemical segment to meet rising demand. Bio-based chemicals EBITDA more than doubled in FY25, indicating strong growth momentum. Strategic diversification into bio-butanol and higher alcohols (licensed technology) expected to boost revenues over next few

Future growth expectations in earnings/operating earnings/profits/EPS?

Godavari Biorefineries targets a significant growth with EBITDA expected to increase approximately 3x of FY25 numbers by FY29. Strategic growth drivers include expansion in bio-based specialty chemicals and multi-feedstock ethanol capacity, including grain/maize-based ethanol commissioning in Q4 FY26. The company anticipates operational efficiencies, debottlenecking chemical capacities, and launching new high-margin specialty chemicals to drive profitability. Bio-based chemicals segment EBITDA more than doubled in FY25 and is expected to grow further with licensed biobutanol technology a

Godavari Bioref.Q4 FY25Diversified FMCG

Godavari Bioref. Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹227P/E: 41.7Market Cap: ₹1.2K CrSector: Diversified FMCG

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Godavari Biorefineries targets a 3x increase in EBITDA by FY29, driven by growth in ethanol and bio-based specialty chemicals.
Ethanol segment growth supported by commissioning of 200-kiloliter/day grain/maize-based distillery in Q4 FY26, adding multi-feedstock capacity.
Continued de-bottlenecking and capacity expansions planned for bio-based chemical segment to meet rising demand.
Bio-based chemicals EBITDA more than doubled in FY25, indicating strong growth momentum.
Strategic diversification into bio-butanol and higher alcohols (licensed technology) expected to boost revenues over next few years.
Expansion plans include increased ethanol production from B heavy molasses, sugarcane juice/syrup, and new feedstocks like grain and maize.
Long-term growth driven by co-creation with customers focused on green chemicals and energy transition.
Expect revenue and margin expansion progress to become evident progressively through FY27-29.

Margin guidance

Category 3

Godavari Biorefineries targets a significant growth with EBITDA expected to increase approximately 3x of FY25 numbers by FY29.
Strategic growth drivers include expansion in bio-based specialty chemicals and multi-feedstock ethanol capacity, including grain/maize-based ethanol commissioning in Q4 FY26.
The company anticipates operational efficiencies, debottlenecking chemical capacities, and launching new high-margin specialty chemicals to drive profitability.
Bio-based chemicals segment EBITDA more than doubled in FY25 and is expected to grow further with licensed biobutanol technology and capacity enhancements.
The grain-based ethanol facility investment of ~INR130 crores is expected to support future growth in energy segment.
Overall, the company expects sustained revenue growth and margin expansion fueled by multiple feedstock flexibility, green energy transition, and steady operational improvements.
Earnings growth aligned with these initiatives is expected to strengthen PAT and EPS in the medium term up to FY29.

See what Godavari Bioref. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any current or planned fundraising through debt or equity in the transcript.
The company has strengthened its financial position by reducing debt, which has lowered its interest burden and created headroom for future expansion and strategic investments.
Capex plans for FY26 include approximately INR130 crores for the grain-based ethanol facility and investments in debottlenecking bio-based chemicals and biobutanol projects.
The company is working on detailed engineering packages for expansion but has not provided firm capital expenditure figures or fundraising requirements yet.
Any further clarity on capital expenditure and potential funding needs will be shared in future updates or board meetings.

Order book

The provided transcript from the Q4 and FY25 earnings call of Godavari Biorefineries Limited does not explicitly mention the current or expected order book or pending orders in specific terms. However, related insights include: - The company is actively working on de-bottlenecking its chemical capacities to meet growing demand, indicating ongoing and incoming orders in the bio-based specialty chemicals segment. - There is active customer engagement and co-creation for bio-based specialty chemicals and biobutanol, reflecting a growing order pipeline. - The grain/maize-based ethanol facility commissioning is expected in Q4 FY26, supporting anticipated future orders in ethanol production. - The company has fulfilled its sugar export quota and has stocks of B heavy molasses to be converted into ethanol, indicating ongoing production commitments. No direct quantitative data on order book size or pending orders was disclosed.

See what Godavari Bioref. management said on order book — free account, 30 seconds.

Capex plans

Yes

Godavari Biorefineries is investing in a grain/maize-based ethanol facility with a capacity of 200,000 liters per day, expected to be commissioned in Q4 FY26, with an estimated capex of INR 130 crores (net of GST).
The company is undertaking debottlenecking initiatives to optimize bio-based specialty chemical production capacity, supporting growth in this segment.
Engineering work is underway for a biobutanol project licensed from Catalyxx, which will expand their sustainable chemistry portfolio; detailed engineering design is in progress.
Continuous maintenance capex is also planned annually as part of regular operations.
Overall capex will support achieving a targeted 3x EBITDA growth by FY29, driven by expansions in both ethanol and specialty chemical segments.

Track Godavari Bioref. — get its next earnings analysis in your feed

How does Godavari Bioref. rank vs peers in Diversified FMCG?

Pro feature

ThisGodavari Bioref.

Rev 2Mar 3

See where Godavari Bioref. sits in Diversified FMCGSee which companies these are, and every other name in the sector.Open rankings

How does Godavari Bioref. rank in Diversified FMCG?

Compare Godavari Bioref. against every Diversified FMCG company (Q4 FY25) on revenue, margins and earnings-call signals.

View Diversified FMCG leaderboard →

What Godavari Bioref.'s management said in earlier quarters

Others in Diversified FMCG this season

ITC Ltd (Q2 FY25)
1,457 crore (versus Rs. Key concall takeaways from ITC Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
ITC Ltd (Q3 FY25)
8,344 crore. Key concall takeaways from ITC Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
ITC Ltd (Q4 FY25)
Q4 FY25 Gross Revenue: ₹18,266 crore, up 9.2% YoY (Page 42) . Key concall takeaways from ITC Ltd's Q4 FY25 earnings call — and how it ranks against sector…
ITC Ltd (Q1 FY26)
20,911 crore, up 19.8% YoY (Page 41) . Key concall takeaways from ITC Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Hind. Unilever vs ITC Ltd vs Hindustan Foods

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →